Biovail’s Ralivia receives approvable letter

Share this article:
An item appearing in the December issue of Medical Marketing and Media (Pipeline, page 10) incorrectly stated that Biovail's Ralivia ER (tramadol hydrochloride) had received FDA approval.
Biovail has received an approvable letter from the FDA for the drug, but it has yet to be approved.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Researchers hit links for charity

The PMR Charities Golf Classic teed up more than $20,000 for St. Jude Children's Research Hospital.

FDA to review Neupogen biosimilar

Novartis subsidiary Sandoz announced Thursday that the FDA has agreed to review its filgrastim biosimilar which is already approved in 40 countries.

FDA approves a new painkiller

Targiniq ER combines the prescription opioid oxycodone and naloxone, which is often used to treat overdoses.